Minimal Residual Disease–Guided Therapy in Childhood Acute Leukemia
International Journal of Current Pharmaceutical Review and Research · 31.03.2026 · 18 (03)
DOI: 10.25258/ijcpr.18.3.300 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Current Pharmaceutical Review and Research, online erschienen am 31.03.2026. Verfasst von Ashutosh Kumar Verma und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Minimal residual disease (MRD) has emerged as a critical prognostic marker in childhood acute leukemia, enabling risk-adapted therapy and improved survival outcomes. MRD-guided therapeutic strategies help in identifying patients at high risk of relapse and tailoring treatment intensity accordingly.
Objective
To evaluate the clinical impact of MRD-guided therapy on treatment outcomes in children with acute leukemia.
Methods
A retrospective study was conducted at Mahavir Cancer Sansthan, Patna, over a period of 8 months. A total of 200 pediatric patients diagnosed with acute leukemia were included. MRD status was assessed using flow cytometry at defined treatment intervals. Patients were stratified into MRD-negative and MRD-positive groups, and outcomes were compared.
Results
MRD negativity was achieved in 68% of patients after induction therapy. The MRD-negative group showed significantly higher remission rates (92% vs. 61%, p
Zitieren
APA
Verma, A. K., Sajid, M., & Shrivastava, N. (2026). Minimal Residual Disease–Guided Therapy in Childhood Acute Leukemia. International Journal of Current Pharmaceutical Review and Research, 18(03). https://doi.org/10.25258/ijcpr.18.3.300
Vancouver
Verma AK, Sajid M, Shrivastava N. Minimal Residual Disease–Guided Therapy in Childhood Acute Leukemia. International Journal of Current Pharmaceutical Review and Research. 2026;18(03). doi:10.25258/ijcpr.18.3.300
BibTeX
@article{Verma2026,
author = {Verma, Ashutosh Kumar and Sajid, Md and Shrivastava, Neha},
title = {Minimal Residual Disease–Guided Therapy in Childhood Acute Leukemia},
journal = {International Journal of Current Pharmaceutical Review and Research},
year = {2026},
volume = {18},
number = {03},
doi = {10.25258/ijcpr.18.3.300}
}
EUVIMED